Kate Sasser
About
Kate Sasser is a scholar working on Oncology, Hematology and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Kate Sasser has authored 41 papers receiving a total of 504 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 14 papers in Hematology and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kate Sasser's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Multiple Myeloma Research and Treatments (11 papers) and Cancer Genomics and Diagnostics (8 papers). Kate Sasser is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Multiple Myeloma Research and Treatments (11 papers) and Cancer Genomics and Diagnostics (8 papers). Kate Sasser collaborates with scholars based in United States, Netherlands and Belgium. Kate Sasser's co-authors include Parul Doshi, Lanxi Song, Soner Altiok, Eric B. Haura, William J. Fulp, Matthew A. Smith, Christopher Chiu, Amy Axel, Joyce Meesters and Marcel Roza and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Kate Sasser
33 papers receiving 497 citations
Peers
Kate Sasser
Homer Adams United States
Marloes E.C. Broekmans Netherlands
Fabrizio Accardi Italy
Ivana Catacchio Italy
Lida Pacaud United States
María Hernández‐Sánchez Spain
Nadia Peragine Italy
Margot Jak Netherlands
Morten Orebo Holmström Denmark
Michael S. van der Veer Netherlands
Citations per year, relative to Kate Sasser Kate Sasser (= 1×)
peers
Homer Adams
Countries citing papers authored by Kate Sasser
Since
Specialization
Citations
This map shows the geographic impact of Kate Sasser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate Sasser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate Sasser more than expected).
Fields of papers citing papers by Kate Sasser
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Kate Sasser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate Sasser. The network helps show where Kate Sasser may publish in the future.
Co-authorship network of co-authors of Kate Sasser
This figure shows the co-authorship network connecting the top 25 collaborators of Kate Sasser. A scholar is included among the top collaborators of Kate Sasser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate Sasser. Kate Sasser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ben‐Shachar, Rotem, Josephine Feliciano, Kyle A. Beauchamp, et al.. (2024). Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open. 7(11). e2442970–e2442970.
2.
Nakamura, Yoshiaki, Kristiyana Kaneva, Christine Lo, et al.. (2024). Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in patients with resected stage II and III colorectal cancer: A subset analysis from the GALAXY study in CIRCULATE-Japan.. Journal of Clinical Oncology. 42(16_suppl). 3618–3618.
3.
Driessen, Terri M., Christine Lo, Wei Zhu, et al.. (2024). Abstract 3498: A novel combination of tissue-informed, comprehensive genomic profiling (CGP) and non-bespoke blood-based profiling for quantifying circulating tumor DNA (ctDNA). Cancer Research. 84(6_Supplement). 3498–3498.
4.
Nakamura, Yoshiaki, Kristiyana Kaneva, Christine Lo, et al.. (2024). Predicting recurrence using a tumor-uninformed ctDNA assay detecting MRD in patients with resected stage II or III colorectal cancer: Subset analysis from the GALAXY study in CIRCULATE-Japan.. Journal of Clinical Oncology. 42(3_suppl). 21–21.
5.
Stein, Michelle M., Kristiyana Kaneva, Seung Won Hyun, et al.. (2024). Abstract 3676: A circulating tumor fraction DNA biomarker response stratified by ESR1 mutation status correlates with overall survival in patients with HR+ HER2- metastatic breast cancer. Cancer Research. 84(6_Supplement). 3676–3676.
6.
Stein, Michelle M., Paul Fields, Luca Lonini, et al.. (2023). 163 A multi-modal, pan-cancer atlas of tumor-immune states across primary and metastatic disease using a large, real-world database. SHILAP Revista de lepidopterología. A182–A184.
7.
Li, Tommy, Ida H. Hiemstra, Christopher Chiu, et al.. (2022). Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas. Clinical Pharmacology & Therapeutics. 112(5). 1108–1119.
8.
Imle, Andrea, Aras Toker, Kristin Strumane, et al.. (2022). 1070 HexaBody-CD27 enhances T-cell activation, proliferation, cytokine secretion and cytotoxic activity independently of Fc gamma receptor-mediated crosslinking. Regular and Young Investigator Award Abstracts. A1112–A1112.
9.
Jabado, Omar, Suzana S. Couto, Brandon W. Higgs, et al.. (2022). DLBCL cell of origin typing and whole transcriptome analysis using single slides with HTG EdgeSeq.. Journal of Clinical Oncology. 40(16_suppl). 7576–7576.
10.
Lynch, Kevin, Dawn Swan, Robert B. Henderson, et al.. (2021). Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. OncoImmunology. 10(1). 1859263–1859263.
11.
Zhang, Zeyu, Yaning Yang, Hongyan Fang, et al.. (2020). A forward selection algorithm to identify mutually exclusive alterations in cancer studies. Journal of Human Genetics. 66(5). 509–518.
12.
Karakasheva, Tatiana A., George A. Dominguez, Ayumi Hashimoto, et al.. (2018). CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. JCI Insight. 3(6).
13.
Sasser, Kate, Tineke Casneuf, Amy Axel, et al.. (2016). Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer Targets and Therapy. 8. 13–13.
14.
Ryan, Aideen E., et al.. (2016). Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP. Blood. 128(22). 2101–2101.
15.
Caillon, Hélène, Jason S. Simon, Amy Axel, et al.. (2016). Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab. Blood. 128(22). 2063–2063.
16.
Lamble, Adam J., Yoko Kosaka, Pierrette Lo, et al.. (2015). Defining the Immune Microenvironment in Patients with Acute Myeloid Leukemia. Blood. 126(23). 1374–1374.
17.
McCudden, Christopher R., Amy Axel, Dominique Slaets, et al.. (2015). Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody.. Journal of Clinical Oncology. 33(15_suppl). 8590–8590.
18.
Song, Lanxi, Matthew A. Smith, Parul Doshi, et al.. (2014). Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer. Journal of Thoracic Oncology. 9(7). 974–982.
19.
Santos, Cédric Dos, Xiaochuan Shan, Chenghui Zhou, et al.. (2014). Anti-Leukemic Activity of Daratumumab in Acute Myeloid Leukemia Cells and Patient-Derived Xenografts. Blood. 124(21). 2312–2312.
20.
Erb, Holger H.H., Patrizia Moser, Florian Handle, et al.. (2013). IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9. Endocrine Related Cancer. 20(5). 677–689.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Homer Adams Breakdown of academic impact, for papers by Marloes E.C. Broekmans Breakdown of academic impact, for papers by Fabrizio Accardi Breakdown of academic impact, for papers by Ivana Catacchio Breakdown of academic impact, for papers by Lida Pacaud Breakdown of academic impact, for papers by María Hernández‐Sánchez Breakdown of academic impact, for papers by Nadia Peragine Breakdown of academic impact, for papers by Margot Jak Breakdown of academic impact, for papers by Morten Orebo Holmström Breakdown of academic impact, for papers by Michael S. van der Veer